Lung Biotechnology Revenue and Competitors

Location

N/A

Total Funding

Pharma

Industry

Estimated Revenue & Valuation

  • Lung Biotechnology's estimated annual revenue is currently $4.4M per year.(i)
  • Lung Biotechnology's estimated revenue per employee is $201,000

Employee Data

  • Lung Biotechnology has 22 Employees.(i)
  • Lung Biotechnology grew their employee count by -4% last year.

Lung Biotechnology's People

NameTitleEmail/Phone
1
Manager Cell Production and Process DevelopmentReveal Email/Phone
2
Manager, Clinical Supply ChainReveal Email/Phone
3
Research Associate IReveal Email/Phone
4
Clinical Trial AdministratorReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$7M35-3%N/AN/A
#2
$7.2M36-5%N/AN/A
#3
$10.5M52-9%N/AN/A
#4
$344.1M17129%N/AN/A
#5
$27.5M1376%N/AN/A
#6
$107.3M5349%N/AN/A
#7
$12.9M6428%N/AN/A
#8
$31.6M1571%N/AN/A
#9
$31.4M1567%N/AN/A
#10
$11.5M5730%N/AN/A
Add Company

What Is Lung Biotechnology?

Lung Biotechnology PBC is a pharmaceuticals company based out of 1040 SPRING ST, Silver Spring, Maryland, United States.

keywords:N/A

N/A

Total Funding

22

Number of Employees

$4.4M

Revenue (est)

-4%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Lung Biotechnology News

2022-04-20 - PDS Biotechnology Announces Conference Call and Webcast ...

PDS Biotechnology Announces Conference Call and Webcast for First ... vulvar) and breast, colon, lung, prostate, and ovarian cancers.

2022-04-17 - AI predicts lung cancer tumor growth after radiation: NHS study

The biotech was founded in 2019, and in April 2021 it raised $92 million in a series B to develop its vaccine in partnership with Walvax...

2022-03-22 - Lung Transplant Rejection Pipeline Analysis | Clinical Trials ...

As the number of lung transplants annually in the US and worldwide has increased, ... Miromatrix Medical, Lung Biotechnology PBC, Haemair,...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$2.2M220%N/A
#2
N/A2210%N/A
#3
$2.3M230%N/A
#4
$2.3M2321%N/A
#5
$4.3M23-12%N/A